This article looks at what a transition to propellants with lower Global Warming Potential will involve and the lessons that can be learned from the industry’s earlier transition from CFCs to HFAs. Key issues that need to be addressed as formulators learn to work with propellants such as HFA 152a and HFO 1234ze include solubility of the active, the profile of the emitted spray, droplet size and evaporation, and electrostatic characteristics.
Aptar Pharma offers a comprehensive suite of services for those looking to accelerate their transition to low carbon MDIs including the Nanopharm SmartTrack™ platform which provides a wealth of information for formulation optimization.
Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery
This Might Also Be of Interest
Digital Health and Digital Therapeutics: Where are we heading and why?
Webinars, Pharmaceutical, Drug Delivery Innovations, Brand Differentiation, Market Insights, Product Solutions
How pMDIs are transforming Asthma and COPD treatments
Publications, Pharmaceutical, Sustainability, Drug Delivery Innovations, Market Insights, Product Solutions
Drug, Device, Digital: Reimagined Healthcare
Webinars, Pharmaceutical, Innovation & Insights, Brand Differentiation, Market Insights, Product Solutions
Supporting Patients and HCPs with New Digital Technology
Publications, Pharmaceutical, Drug Delivery Innovations, Brand Differentiation, Market Insights, Product Solutions
